Category Archives: Regenerative Medicine

stem cell | Advantages Of Cord Blood Banking
http://www.cordbloodrecommendation.com Programs Available to Store the Blood There are a small number of programs in the US currently (December 2011) that save cord blood. Before you decide on a specific cord blood bank, contact the AABB to determine if the private blood bank is accredited or if it has any complaints lodged against the facility by other patrons. It really should be observed that the technique has a high risk of complication. Keep in mind that cord blood storage acts as an insurance policy for your family, so consider any other factors before immediately determining not to store your child #39;s cord blood simply because of price. One more cord blood donation might just be enough to save another life. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. In addition, you have to decide well in advance of the due date because once you lose the precious blood, you cannot regain it. The patient no longer needs to wait for a donor; he can be his own donor if his cord blood had been preserved after his birth. The ultimate decision to bank cord stem cells or not is a personal decision as to what is deemed appropriate for that particular family, but in making that ...From:loshoteles enmedellinViews:0 0ratingsTime:01:31More inScience Technology

Read more:
stem cell | Advantages Of Cord Blood Banking - Video

Nose cell transplant enables paralysed dogs to walk
cientists have reversed paralysis in dogs after injecting them with cells grown from the lining of their nose. The pets had all suffered spinal injuries which prevented them from using their back legs. The Cambridge University team is cautiously optimistic the technique could eventually have a role in the treatment of human patients. The study is the first to test the transplant in "real-life" injuries rather than laboratory animals. Treadmill Of 34 pet dogs on the proof of concept trial, 23 had the cells transplanted into the injury site - the rest were injected with a neutral fluid. Many of the dogs that received the transplant showed considerable improvement and were able to walk on a treadmill with the support of a harness. None of the control group regained use of its back legs. The research was a collaboration between the MRC #39;s Regenerative Medicine Centre and Cambridge University #39;s Veterinary School. Professor Robin Franklin, a regeneration biologist at the Wellcome Trust-MRC Stem Cell Institute and report co-author, said: #39;Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement. "We #39;re confident that the technique might be able to restore at least a small amount of movement in human patients with spinal cord injuries but that #39;s a long way from saying they might be able to regain all lost function. #39; Prof Franklin said the procedure ...From:NEWSHD2012Views:10020 51ratingsTime:00:21More inPets Animals

More:
Nose cell transplant enables paralysed dogs to walk - Video

cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Well, there are still debates on this issue. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. Others choose to donate the blood to a public bank for the public good. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. However, you can choose to make a once-in-a-lifetime decision to collect and store your baby #39;s cord blood stem cells after the birth of your newborn baby. It is able to kill either normal or cancer-producing blood cells of the bone marrow. Your child #39;s umbilical cord blood contains special cells known as stem cells. Thus, it ...From:Alexander santafeViews:0 0ratingsTime:01:31More inScience Technology

Read this article:
cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life - Video

ScienceDaily (Nov. 19, 2012) A research team at Georgetown Lombardi Comprehensive Cancer Center say the new and powerful cells they first created in the laboratory a year ago constitute a new stem-like state of adult epithelial cells. They say these cells have attributes that may make regenerative medicine truly possible.

In the November 19 online early edition of the Proceedings of the National Academy of Sciences (PNAS), they report that these new stem-like cells do not express the same genes as embryonic stem cells and induced pluripotent stem cells (iPSCs) do. That explains why they don't produce tumors when they grow in the laboratory, as the other stem cells do, and why they are stable, producing the kind of cells researchers want them to.

"These seem to be exactly the kind of cells that we need to make regenerative medicine a reality," says the study's senior investigator, chairman of the department of pathology at Georgetown Lombardi, a part of Georgetown University Medical Center.

This study is a continuation of work that led to a breakthrough in December 2011 when Schlegel and his colleagues demonstrated that he and his team had designed a laboratory technique that keep both normal as well as cancer cells alive indefinitely -- which previously had not been possible.

They had discovered that adding two different substances to these cells (a Rho kinase inhibitor and fibroblast feeder cells) pushes them to morph into stem-like cells that stay alive indefinitely. When the two substances are withdrawn from the cells, they revert back to the type of cell that they once were. They dubbed these cells conditionally reprogrammed cells (CRCs).

The advance was seen as an exciting demonstration of personalized cancer medicine. In fact, a case study authored by Schlegel and his team, reported in the September 27 issue of the New England Journal of Medicine (NEJM), demonstrated how CRCs derived from normal and tumor cells of a 24-year-old man with a rare type of lung tumor allowed physicians to identify an effective cancer therapy. These cells were used to screen potential treatments and in this way, the scientists were able to see which therapies were active against the tumor cells and less harmful to the normal cells.

"Our first clinical application utilizing this technique represents a powerful example of individualized medicine," Schlegel said in September. But he cautioned, "It will take an army of researchers and solid science to figure out if this technique will be the advance we need to usher in a new era of personalized medicine."

This study was designed to see how the CRCs compared to known properties of embryonic stem cells and iPSCs, which are adult cells that have been manipulated by addition of genes to make them capable of differentiating (morphing into new adult cell types). Both embryonic stem cells and iPSCs have been investigated for use in regenerative medicine, but each can form tumors when injected into mice and "it is difficult to control what kind of cells these cells differentiate into," Schlegel says. "You may want them to be a lung cell, but they could form a skin cell instead."

In contrast, cells derived from the lung will develop stem-like properties when the conditions are added, allowing expansion of the lung cell population. However, when the conditions are withdrawn, they will revert to differentiated lung cells, he says. Schlegel added that they do this rapidly -- within three days of adding the inhibitor and feeder cells, they efficiently generated large numbers of stem-like cells. It is also completely reversible: when the conditions are taken away, the cells lose their stem-like properties and potentially can be safely implanted into tissue.

The researchers compared gene expression between the three cell types and found that while some of the same genes are expressed in all the cells, CRCs don't over express the same critical genes that embryonic stem cells and iPSCs do. "Because they don't express those genes, they don't form tumors and they are lineage committed, unlike the other cells," Schlegel says. "That shows us that CRCs are a different kind of stem-like cell."

Original post:
'Different kind of stem cell' possesses attributes favoring regenerative medicine

Nose cell transplant enables paralysed dogs to walk
cientists have reversed paralysis in dogs after injecting them with cells grown from the lining of their nose. The pets had all suffered spinal injuries which prevented them from using their back legs. The Cambridge University team is cautiously optimistic the technique could eventually have a role in the treatment of human patients. The study is the first to test the transplant in "real-life" injuries rather than laboratory animals. Treadmill Of 34 pet dogs on the proof of concept trial, 23 had the cells transplanted into the injury site - the rest were injected with a neutral fluid. Many of the dogs that received the transplant showed considerable improvement and were able to walk on a treadmill with the support of a harness. None of the control group regained use of its back legs. The research was a collaboration between the MRC #39;s Regenerative Medicine Centre and Cambridge University #39;s Veterinary School. Professor Robin Franklin, a regeneration biologist at the Wellcome Trust-MRC Stem Cell Institute and report co-author, said: #39;Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement. "We #39;re confident that the technique might be able to restore at least a small amount of movement in human patients with spinal cord injuries but that #39;s a long way from saying they might be able to regain all lost function. #39; Prof Franklin said the procedure ...From:NEWSHD2012Views:2179 8ratingsTime:00:21More inPets Animals

See the original post here:
Nose cell transplant enables paralysed dogs to walk - Video

Call for Nominations: "Stem Cell Person of the Year"
UC Davis stem cell scientist Paul Knoepfler is seeking nominees for the 2012 "Stem Cell Person of the Year." He created the new award to recognize an individual who has made an outstanding difference in the field of stem cell-based cellular and regenerative medicine. Nominees can be scientists, patient advocates, individuals from industry or just about anyone who has made the stem cell field better. The award includes a $1000 cash prize.From:UCDavisHealthViews:60 2ratingsTime:01:48More inScience Technology

Continued here:
Call for Nominations: "Stem Cell Person of the Year" - Video

Bernard Siegel - Aging: The Disease, The Cure, The Implications
Bernard Siegel is the full-time Executive Director of the nonprofit Genetics Policy Institute (GPI) based in Palm Beach Gardens, Florida. He received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975. In 2002, Mr. Siegel filed the landmark case seeking a guardian for the alleged clone, "Baby Eve." The case was widely credited for exposing Clonaid , the so-called "human cloning company" as a sham. In 2003, he traded his 30-year courtroom career to found GPI, which leads the global cause in support of stem cell research. He is a recognized policy expert relating to stem cell research, regenerative medicine and cloning. Working with the world #39;s leading stem cell researchers, Mr. Siegel played a pivotal role in protecting the research in the United Nations, which was under the threat of being banned by world treaty. He also works with grassroots activists throughout the United States, educating lawmakers and formulating effective strategies supporting research for cures. Mr. Siegel serves on the board of directors of Americans for Cures and on the advisory boards of the Sabrina Cohen Foundation for Stem Cell Research, The Brooke Ellison Project and Genomics Education Institute. He is a member of the American Society for Bioethics + Humanities. He is a member of the International Society for Stem Cell Research and serves as the co-chair of the ISSCR Governmental Affairs Committee. Mr. Siegel has been ...From:Jeriaska JeriaskaViews:0 0ratingsTime:18:57More inEducation

Read more:
Bernard Siegel - Aging: The Disease, The Cure, The Implications - Video

GIA announces the release of a comprehensive global report on Regenerative Medicine markets. Global market for Regenerative Medicine is projected to exceed US$4.4 billion by 2018, driven by technological advances and favorable demographics. Potentially huge savings on the medical care front and enhanced healing capabilities of regenerative medicine are expected to be the major contributing factors for market growth. Supportive political actions, Government funding, corporate investment, clinical outcomes, increased awareness, increased endorsement from doctors, enhanced manufacturing technologies, and novel sources of stem cells are also expected to impart momentum to the growth of Regenerative Medicine.

San Jose, California (PRWEB) November 16, 2012

Though the current market for regenerative medicine is small in size, the market for tissue engineering holds the potential to reach enormous levels in the coming decade. Growth in the regenerative medicine market is forecast to be propelled by new products to be introduced in the segments of orthopedics, neurology, organ regeneration, wound care, cardiovascular, and urology. With the strengthening of existing markets, the regenerative medicine market is also expected to witness penetration in other markets including Japan, Europe and other emerging countries.

Regenerative Medicine market is presently witnessing the introduction of a limited number of regenerative therapies targeting mainly orthopedics (including bone and joint applications), wound care, and body sculpture. There are a number of therapies in the development pipeline addressing potential areas such as Cardiovascular, Nerve repair, Diabetes and Inflammatory diseases among others. In addition, the future is also expected to witness the introduction of laboratory grown tissue engineered organs and tissues. However, the development of fully functional organs is expected to be very complex and the prediction of the success of this attempt is impossible at present. As an alternative to this approach, attempts to develop the organ in parts are also going on which is relatively less complicated and offer higher success rates.

Orthopedics segment which includes spine, bone grafts and bone substitutes is the largest among the different fields of global regenerative medicine market. Advancements in the biological science has drastically revolutionized regenerative medicine domain. Specifically, regenerative medicine in bone and joint applications made huge strides over the past few years. Healthy growth in the bone and joint applications is primarily due to the ageing baby boomer population and escalating incidence of osteoporosis, arthritis, and several other bone and joint traumas, including knee injuries and hip fractures. Growing awareness among people for regenerative medicines and increasing usage of non-autograft products by doctors and medical personnel are also stimulating growth for these products.

As stated by the new market research report on Regenerative Medicine, the US represents the largest market worldwide. Though the US is expected to retain its leading position, growth in other markets such as Japan is forecast to be higher than that of the US. The higher growth expected in the other markets is attributed to the level of Government as well as public support for the Regenerative Medicine sector. Though the US spends a substantial amount in the area of research, other Governments are also increasing their support for the sector. Bone Replacements represents the largest application for Regenerative Medicine in Bone and Joint Applications, while Tissue Replacements represents the application with highest potential for growth.

The global regenerative medicine market consists of companies engaged in harvesting, processing, purification, cryopreservation, storage, administration, or research activities of cells and tissue-based products. Major players in the global marketplace include BioVest International Inc., Curis Inc., Cytori Therapeutics Inc., Evotec AG, Forticell Bioscience Inc., Geron Corporation, Integra LifeSciences Corporation, LifeCell Corporation, Osiris Therapeutics Inc., Tengion Inc., Tepha Inc., and TiGenix N.V.

The research report titled "Regenerative Medicine: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, regulatory scenario, company profiles, mergers, acquisitions, and other strategic industry activities. The report provides market estimates and projections for Regenerative Medicine Products for Bone and Joint Applications (in US$) by Bone Replacements, Bone Stimulators, and Tissue Replacements applications. Geographic markets analyzed include the United States, Europe and Rest of World.

For more details about this comprehensive market research report, please visit

http://www.strategyr.com/Regenerative_Medicine_Market_Report.asp

Go here to read the rest:
Technological Advances and Favorable Demographics Drives the Regenerative Medicine Market, According to New Report by ...

Call for Nominations: "Stem Cell Person of the Year"
UC Davis stem cell scientist Paul Knoepfler is seeking nominees for the 2012 "Stem Cell Person of the Year." He created the new award to recognize an individual who has made an outstanding difference in the field of stem cell-based cellular and regenerative medicine. Nominees can be scientists, patient advocates, individuals from industry or just about anyone who has made the stem cell field better. The award includes a $1000 cash prize.From:UCDavisHealthViews:2 0ratingsTime:01:48More inScience Technology

Link:
Call for Nominations: "Stem Cell Person of the Year" - Video

GIA announces the release of a comprehensive global report on Regenerative Medicine markets. Global market for Regenerative Medicine is projected to exceed US$4.4 billion by 2018, driven by technological advances and favorable demographics. Potentially huge savings on the medical care front and enhanced healing capabilities of regenerative medicine are expected to be the major contributing factors for market growth. Supportive political actions, Government funding, corporate investment, clinical outcomes, increased awareness, increased endorsement from doctors, enhanced manufacturing technologies, and novel sources of stem cells are also expected to impart momentum to the growth of Regenerative Medicine.

San Jose, California (PRWEB) November 16, 2012

Though the current market for regenerative medicine is small in size, the market for tissue engineering holds the potential to reach enormous levels in the coming decade. Growth in the regenerative medicine market is forecast to be propelled by new products to be introduced in the segments of orthopedics, neurology, organ regeneration, wound care, cardiovascular, and urology. With the strengthening of existing markets, the regenerative medicine market is also expected to witness penetration in other markets including Japan, Europe and other emerging countries.

Regenerative Medicine market is presently witnessing the introduction of a limited number of regenerative therapies targeting mainly orthopedics (including bone and joint applications), wound care, and body sculpture. There are a number of therapies in the development pipeline addressing potential areas such as Cardiovascular, Nerve repair, Diabetes and Inflammatory diseases among others. In addition, the future is also expected to witness the introduction of laboratory grown tissue engineered organs and tissues. However, the development of fully functional organs is expected to be very complex and the prediction of the success of this attempt is impossible at present. As an alternative to this approach, attempts to develop the organ in parts are also going on which is relatively less complicated and offer higher success rates.

Orthopedics segment which includes spine, bone grafts and bone substitutes is the largest among the different fields of global regenerative medicine market. Advancements in the biological science has drastically revolutionized regenerative medicine domain. Specifically, regenerative medicine in bone and joint applications made huge strides over the past few years. Healthy growth in the bone and joint applications is primarily due to the ageing baby boomer population and escalating incidence of osteoporosis, arthritis, and several other bone and joint traumas, including knee injuries and hip fractures. Growing awareness among people for regenerative medicines and increasing usage of non-autograft products by doctors and medical personnel are also stimulating growth for these products.

As stated by the new market research report on Regenerative Medicine, the US represents the largest market worldwide. Though the US is expected to retain its leading position, growth in other markets such as Japan is forecast to be higher than that of the US. The higher growth expected in the other markets is attributed to the level of Government as well as public support for the Regenerative Medicine sector. Though the US spends a substantial amount in the area of research, other Governments are also increasing their support for the sector. Bone Replacements represents the largest application for Regenerative Medicine in Bone and Joint Applications, while Tissue Replacements represents the application with highest potential for growth.

The global regenerative medicine market consists of companies engaged in harvesting, processing, purification, cryopreservation, storage, administration, or research activities of cells and tissue-based products. Major players in the global marketplace include BioVest International Inc., Curis Inc., Cytori Therapeutics Inc., Evotec AG, Forticell Bioscience Inc., Geron Corporation, Integra LifeSciences Corporation, LifeCell Corporation, Osiris Therapeutics Inc., Tengion Inc., Tepha Inc., and TiGenix N.V.

The research report titled "Regenerative Medicine: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, regulatory scenario, company profiles, mergers, acquisitions, and other strategic industry activities. The report provides market estimates and projections for Regenerative Medicine Products for Bone and Joint Applications (in US$) by Bone Replacements, Bone Stimulators, and Tissue Replacements applications. Geographic markets analyzed include the United States, Europe and Rest of World.

For more details about this comprehensive market research report, please visit

http://www.strategyr.com/Regenerative_Medicine_Market_Report.asp

See the rest here:
Technological Advances and Favorable Demographics Drives the Regenerative Medicine Market, According to New Report by ...